Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9619561 | 0.76 | POLB (0.46) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL11420240 | 0.75 | RAPGEF4 (0.43) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL242786 | 0.75 | RAPGEF4 (0.43) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL6571405 | 0.74 | RAPGEF4 (0.43) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| Phosphine SCHEMBL22634061 | 0.73 | RAPGEF4 (0.41) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL10798387 | 0.73 | RAPGEF4 (0.41) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL129762 | 0.73 | ACHE (0.57) | RAPGEF4ACHEALDH1A1MAPTLMNA | |
| SCHEMBL3753026 | 0.72 | MAPT (0.38) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL7023644 | 0.71 | RAPGEF4 (0.39) | RAPGEF4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL15364372 | 0.71 | RAPGEF4 (0.39) | RAPGEF4ACHEALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4707161-A | Lightfastness of dyeings obtained with acid dyes or metal complex dyes on polyamides: treatment with copper hydroxamates | BASF AKTIENGESELLSCHAFT (DE) | 1987-11-17 | — | — | US | claimed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1931425-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-0107615-B1 | POLYOLEFINS STABILIZED BY BIS OR TRIS (POLYALKYLPIPERIDINYL-AMINO) 1,3,5-TRIAZINES | CIBA-GEIGY AG (CH) | 1992-10-28 | — | — | EP | disclosed |
| US-5102927-A | Againts oxidative and light induced degradation | CIBA-GEIGY CORPORATION (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0254987-B1 | BENZOPHENONE ETHER-ESTERS AND PROCESS FOR IMPROVING THE LIGHT FASTNESS OF POLYESTER COLOURINGS BY THE USE OF BENZOPHENONE ETHER-ESTERS | BASF Aktiengesellschaft (DE) | 1992-03-04 | — | — | EP | disclosed |
| EP-0446740-A2 | Utilization of benzophenone-derivatives as antiluminous agents for aromatic polycarbonates and polyestercarbonates | BASF Aktiengesellschaft (DE) | 1991-09-18 | — | — | EP | disclosed |
| US-4789382-A | WITH DISPERSE DYES, READY EXHAUSTION, SUBLIMATION RESISTANT, BRIGHT | BASF AKTIENGESELLSCHAFT (DE) | 1988-12-06 | — | — | US | disclosed |
| EP-0254987-A2 | Benzophenone ether-esters and process for improving the light fastness of polyester colourings by the use of benzophenone ether-esters | BASF Aktiengesellschaft (DE) | 1988-02-03 | — | — | EP | disclosed |
| US-4707161-A | Lightfastness of dyeings obtained with acid dyes or metal complex dyes on polyamides: treatment with copper hydroxamates | BASF AKTIENGESELLSCHAFT (DE) | 1987-11-17 | — | — | US | disclosed |
| EP-0227640-A1 | Polyolefins stabilised by bis-(polyalkylpiperidinyl-amino)-1,3,5-triazines | CIBA-GEIGY AG (CH) | 1987-07-01 | — | — | EP | disclosed |
| US-4613334-A | COPPER HYDROXAMATE TREATMENT | BASF AKTIENGESELLSCHAFT (DE) | 1986-09-23 | — | — | US | disclosed |
| EP-0107615-A1 | Polyolefins stabilized by bis or tris (polyalkylpiperidinyl-amino) 1,3,5-triazines | CIBA-GEIGY AG (CH) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAPGEF4 4239/4885ACHE 2191/4885ALDH1A1 704/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAPGEF4 4239/4885ACHE 2191/4885ALDH1A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.